Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
4/2006
vol. 108 abstract:
Review article
Pegaptanib sodium in treatment of wet AMD
Magdalena Ulińska
1
Online publish date: 2006/12/21
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Taking into consideration that the advanced stage of Age related Macular Degeneration is a very common cause of social blindness and present results of laser photocoagulation, PDT treatment and TTT are not satisfying, it seems to be of huge importance to look for new types of treatment, to improve visual outcomes.
Repeated intravitreal injection of pegaptanib sodium (a VEGF aptamer) is a modern procedure which may not only give stabilization of visual acuity, but it may also lead to the improvement in high percentage. In this paper there is a short update on the epidemiology and the symptoms of the disease and the role of VEGF and its isoforms expression in the development of wet AMD. The presentation of pegaptanib sodium (Macugen®) focus on its mechanism of action. Finally V.I.S.I.O.N. trial results are presented to show encouraging efficacy of the procedure. keywords:
age related macular degeneration (AMD), choroidal neovascularization, pegaptanib sodium, intravitreal injection |
|